TG Therapeutics Announces Special Protocol Assessment Agreement With the FDA for the First Phase 3 Clinical Trial of Its Proprietary Combination Regimen of TG-1101 in Combination With TGR-1202 for Patients With Chronic Lymphocytic Leukemia